{"filings":[{"id":2447517,"accession_number":"0001104659-26-100470","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-08-25T10:01:24+00:00","items":["3.01","7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.","Scheme expected effective Sept 3, 2026; BRNS ADSs to halt trading before market open that day.","Court hearing for scheme set for Sept 1, 2026 at Royal Courts of Justice, London.","After close, Topco renamed Clywedog Therapeutics Holdings, Inc., trading as CLYD on Nasdaq.","Company to delist ADSs from Nasdaq and file Form 15 to suspend reporting obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088916,"accession_number":"0001628280-26-053940","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-08-06T12:49:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.","Completed enrollment in MAD portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data expected Q4 2026.","Proposed merger with Clywedog expected to close H2 2026; combined company to trade as CLYD.","Received Nasdaq extension to Dec 28, 2026 to regain bid price compliance; ADS transferred to Nasdaq Capital Market.","R&D expenses $3.9M (up from $3.6M Q1); G&A expenses $7.1M (up from $2.5M) due to FX losses and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1414963,"accession_number":"0001104659-26-080308","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-07-02T20:05:21+00:00","items":["5.07","8.01"],"status":"ready","headline":"Barinthus Biotherapeutics gets Nasdaq extension to Dec 28, 2026; listing moved to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension from Nasdaq until Dec 28, 2026 to regain $1.00 minimum bid price for ADSs.","ADS listing transferred from Nasdaq Global Market to Nasdaq Capital Market effective July 2, 2026.","Company may consider reverse stock split to regain compliance; no assurance of success.","If bid price does not close at $1.00 for 10 consecutive days by Dec 28, 2026, ADSs may be delisted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563117,"accession_number":"0001104659-26-064761","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-05-21T10:03:12+00:00","items":["5.07"],"status":"ready","headline":"Barinthus shareholders approve Scheme of Arrangement with 99.98% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Court Meeting: 99.98% by value of Scheme Shares voted for the Scheme of Arrangement (24,709,337 for, 3,772 against).","General Meeting: 99.98% of votes cast approved the Scheme Implementation Proposal (24,710,187 for, 3,922 against, 10 abstentions).","Both meetings held May 20, 2026; total Scheme Shares entitled to vote: 40,848,893.","All matters submitted were approved; results are final."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95912,"accession_number":"0001828185-26-000018","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.","Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.","Merger with Clywedog expected mid-2026; combined company to trade as CLYD.","Doug Swirsky appointed CFO effective May 1, 2026.","VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95911,"accession_number":"0001104659-26-046861","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.","Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.","Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.","Company will provide D&O insurance and indemnification on terms no less favorable than other officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109340,"accession_number":"0001104659-26-037698","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus Bio principal accounting officer Gemma Jones to step down April 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gemma Jones, serving as principal accounting officer via CFGI, notified company of resignation effective April 30, 2026.","No successor has been named as of the filing date.","Jones provided services as an employee of CFGI; her departure is from the accounting officer role only.","Company expects transition to be managed internally until a replacement is found."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109339,"accession_number":"0001828185-26-000011","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.","Cash, cash equivalents & restricted cash $71.9M at Dec 31, 2025, down from $112.4M YoY.","Net loss of $66.5M ($1.64 per share) in 2025 vs $61.1M ($1.55) in 2024.","R&D expenses decreased to $25.6M from $42.2M due to deprioritization of legacy assets.","VTP-1000 multiple ascending dose data in celiac expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109338,"accession_number":"0001104659-26-018283","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Barinthus (BRNS) amends merger with Clywedog: exchange ratios set, timeline extended to June 30, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scheme Exchange Ratio set between 0.1 and 0.166667; Merger Exchange Ratio set between 0.000305 and 0.000508.","Post-closing ownership: Beacon shareholders ~34%, Clywedog stockholders ~66% on fully diluted basis.","Beacon minimum cash requirements extended to June 30, 2026 ($20.47M); Clywedog minimum to $1M by May 31, 2026.","Amendment cites unexpected delay from U.S. federal government shutdowns as reason for extended timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109337,"accession_number":"0001828185-26-000004","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).","Company has 180 calendar days, until June 29, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not compliant by deadline, a second 180-day period may be available if certain conditions are met; company evaluating options including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125817,"accession_number":"0001828185-25-000075","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.","Dose-dependent pharmacological effect observed across 18 patients in three cohorts.","MAD portion with gluten challenge ongoing; data expected in second half of 2026.","VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125816,"accession_number":"0001828185-25-000071","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.","Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.","Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.","VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.","Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142554,"accession_number":"0001104659-25-094754","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.","Clywedog stockholders to own ~66% of combined entity; Barinthus shareholders ~34%.","Topco may launch self-tender offer for up to $27M of its common stock prior to Merger close.","Deal expected to close in H1 2026, subject to shareholder approvals, court sanction, antitrust clearance, and Nasdaq listing.","Voting agreements cover ~25% of Barinthus shares and all Clywedog shares; lock-ups for six months for certain insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142552,"accession_number":"0001104659-25-075707","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.","Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.","R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.","VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.","Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142553,"accession_number":"0001828185-25-000058","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.","Q2 net loss $21.1M vs $19.7M in Q1; diluted EPS -$0.52 vs -$0.49.","R&D expenses $8.0M in Q2, down from $8.3M Q1; VTP-1000 celiac trial lead driver.","Phase 1 AVALON SAD final cohort ongoing; topline data expected early Q4 2025.","MAD portion of AVALON started July 2025; data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160613,"accession_number":"0001104659-25-058141","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Barinthus Biotherapeutics shareholders approve all proposals at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resolutions to re-elect directors Pierre A. Morgon and Joseph C. Scheeren passed with ~98.9% of votes cast.","PricewaterhouseCoopers LLP re-appointed as U.K. statutory auditors and ratified as independent auditor for FY2025.","Shareholders approved director remuneration policy and advisory compensation report for FY2024.","No dividend recommended for FY2024; statutory accounts received and noted.","Quorum achieved with 26,993,016 ordinary shares present or represented (66.9% of entitled shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160612,"accession_number":"0001828185-25-000036","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.","Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.","CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.","HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.","IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178848,"accession_number":"0001828185-25-000018","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.","Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.","Revenue $15.0M from Vaxzevria royalties (no future payments expected).","Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.","VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178847,"accession_number":"0001828185-25-000004","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.","CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.","Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.","Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.","Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195517,"accession_number":"0001828185-24-000093","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.","Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.","Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.","Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.","Transition expected to be smooth; Pelletier will remain until responsibilities transitioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195516,"accession_number":"0001828185-24-000089","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.","HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.","In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.","Both regimens were generally well tolerated with no treatment-related SAEs reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195515,"accession_number":"0001828185-24-000083","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.","Cash and equivalents $106.1M at Sep 30, 2024, down from $117.8M at Jun 30; cash runway now into Q2 2026.","HBV003 trial of VTP-300 in chronic hepatitis B fully enrolled (121 participants); updated data at AASLD Nov 2024 as late-breaking abstracts.","VTP-1000 Phase 1 AVALON trial in celiac disease initiated; VTP-850 Phase 1 PCA001 trial completed enrollment (22 participants)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":14969000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211782,"accession_number":"0001104659-24-097364","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus Biotherapeutics promotes Graham Griffiths to COO effective Sept 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Graham Griffiths promoted from Chief Business Officer to COO, effective Sept 1, 2024.","Salary increased to £336,144 in connection with the promotion.","Griffiths joined Barinthus in Oct 2017; previously COO and co-founder of Agalimmune Ltd.","No related party transactions or family relationships with directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211781,"accession_number":"0001828185-24-000073","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.","Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.","Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.","Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.","Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230530,"accession_number":"0001104659-24-070834","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.","Company to undergo restructuring with workforce reduction of approximately 25% to align resources.","Cash runway expected to extend into second quarter of 2026 due to streamlined pipeline and cost cuts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230529,"accession_number":"0001828185-24-000063","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.","IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.","84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.","All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.","Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230528,"accession_number":"0001828185-24-000060","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Barinthus shareholders approve all proposals at 2024 AGM, re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three directors re-elected: William Enright, Alex Hammacher, Robin Wright with >98% of votes cast.","PricewaterhouseCoopers LLP reappointed as UK statutory auditors and ratified as independent auditor for FY 2024.","Advisory vote on directors' compensation report for FY 2023 passed with ~99.8% approval.","No dividend for FY 2023 as recommended by directors; annual accounts received.","Broker non-votes were ~3 million shares (about 13.6% of quorum) on certain items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230525,"accession_number":"0001828185-24-000046","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.","Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.","VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.","VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO effective June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230527,"accession_number":"0001828185-24-000034","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).","Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.","R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).","FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230526,"accession_number":"0001828185-24-000022","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Barinthus Bio reports Phase 1b/2 VTP-200 trial: safety met but pooled efficacy not statistically significant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APOLLO trial met primary safety endpoint; VTP-200 well-tolerated with no treatment-related Grade 3+ AEs or SAEs.","Highest hrHPV clearance 60% (group 2, highest ChAdOx dose) vs 33% placebo; cervical lesion clearance 67% (groups 2&5) vs 39% placebo.","Pooled data across all active dose groups showed no statistically significant improvement in hrHPV or cervical lesion clearance vs placebo.","Company evaluating future development options for VTP-200; further analyses ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248913,"accession_number":"0001828185-24-000007","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio FY2023 net loss $73.3M, revenue drops to $0.8M, cash down to $142.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $73.3M ($1.91 per share) vs net income of $5.3M in 2022; revenue fell to $0.8M from $44.7M on lower Vaxzevria royalties.","Cash and equivalents $142.1M at Dec 31, 2023, down from $194.4M; operating cash burn $50.9M.","R&D expenses rose to $44.9M (+$2.5M); G&A surged to $39.8M (+$33.4M) primarily due to a $7.6M foreign exchange loss.","Pipeline: positive HBV VTP-300 Phase 2 data; HPV VTP-200 APOLLO trial final results expected Q2 2024; celiac VTP-1000 Phase 1 initiation planned Q2 2024.","Secured up to $35M from CEPI for MERS candidate VTP-500; renamed from Vaccitech to Barinthus in Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248912,"accession_number":"0001104659-24-001799","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Barinthus Bio reports $142M cash, extends runway to Q4 2025, details 2024 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents: $142M as of Dec 31, 2023; ~38.6M ordinary shares outstanding.","Cash runway extended from Q2 to Q4 2025 by deferring VTP-1100 IND in HPV cancer and phasing manufacturing.","H1 2024: initiate Phase 1 trial of VTP-1000 in Celiac Disease; final Phase 1b/2 VTP-200 (HPV) data.","H1 2024: interim data from HBV003 (Phase 2b VTP-300 dosing) and AB-729-202 (VTP-300 + imdusiran) trials.","H2 2024: interim data from third arm of AB-729-202 adding nivolumab to VTP-300 and imdusiran."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266458,"accession_number":"0001104659-23-128782","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Barinthus secures up to $34.8M CEPI funding for MERS vaccine VTP-500 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEPI to provide $34.8M to advance VTP-500 through Phase II trials and develop 100,000-dose ready reserve.","VTP-500 received EMA PRIME designation in December 2023, supporting accelerated regulatory review.","Barinthus retains ownership of IP; will pay CEPI mid-single digit royalties on net sales and mid-double digit revenue share.","Partnership with University of Oxford builds on ChAdOx1 platform used in Oxford-AstraZeneca COVID-19 vaccine.","Equitable access commitments: LMICs receive vaccine at cost plus 10%; CEPI can support technology transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266457,"accession_number":"0001104659-23-116327","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio presents interim Phase 2b HBV003 and Phase 2a AB-729-202 data for VTP-300 in chronic HBV at AASLD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.","In AB-729-202, all VTP-300 treated patients maintained HBsAg <100 IU/mL through week 48; 60% maintained <10 IU/mL.","Seven HBV003 participants met criteria for NUC discontinuation; three discontinued NUC therapy.","No treatment-related serious adverse events were reported in either trial.","Data presented in collaboration with Arbutus Biopharma (ABUS) for imdusiran plus VTP-300 combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266456,"accession_number":"0001104659-23-116280","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio reports Q3 net loss $14.1M; cash $160.3M, runway to Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.1M ($0.37 per share) in Q3 2023, compared to $23.8M loss ($0.62 per share) in Q2 2023.","Cash and cash equivalents $160.3M as of Sep 30, 2023; expects runway into Q2 2025.","R&D expenses $15.1M in Q3, up from $13.5M in Q2, driven by VTP-300 HBV and VTP-850 trials.","Upcoming milestones: interim data from two Phase 2 HBV trials at AASLD Nov 2023; Australia submission for VTP-1000 (celiac).","Company changed name from Vaccitech to Barinthus Biotherapeutics in Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":802000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266455,"accession_number":"0001104659-23-114582","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Barinthus Biotherapeutics (fka Vaccitech) begins trading under BRNS, presents Phase 2 HBV data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company renamed to Barinthus Biotherapeutics; Nasdaq ticker changes from VACC to BRNS effective Nov 7, 2023.","Phase 2 hepatitis B trial data for VTP-300 to be presented at AASLD Liver Meeting Nov 10-14, including combination with imdusiran.","Shareholders approved resolutions authorizing directors to allot shares up to £1,928 nominal and disapply pre-emption rights.","Strategic shift from vaccines to T cell immunotherapies targeting chronic infectious diseases, autoimmunity, and cancer.","Clinical collaboration with Arbutus Biopharma highlighted in late-breaking abstract on VTP-300 plus imdusiran."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283697,"accession_number":"0001104659-23-089578","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.","R&D expense $13.5M, up from $9.8M Q1, driven by HBV and SNAPvax IND-enabling studies.","Cash $173M vs $191.3M at Q1; operating cash burn $17M; expects runway into Q2 2025.","Final HBV002 data presented at EASL; VTP-300 induced HBsAg reductions; interim Phase 2 data expected H2 2023.","CMO Dr. Margaret Marshall retired July 2023; will remain as consultant."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":802000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283696,"accession_number":"0001104659-23-084289","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccitech CMO Dr. Margaret Marshall retires effective July 20, 2023; consulting agreement with continued equity vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Margaret Marshall retired as Chief Medical Officer of Vaccitech effective July 20, 2023.","She will enter into a consulting agreement with the company for continued services.","Certain of her equity interests will continue to vest for a nine-month period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303229,"accession_number":"0001104659-23-073326","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.","Group 3 mean HBsAg reduction 0.76 log10 at 2 months (p<0.001) and 0.98 log10 at 8 months (p<0.001).","VTP-300 monotherapy in Group 2 showed 0.7-1.4 log10 declines in three participants; robust T cell response correlated with HBsAg decline.","Phase 2b trial HBV003 >40% enrolled (48/120); interim data expected Q4 2023.","Phase 2a trial with Arbutus (VTP-300 after AB-729) in 40 patients; interim data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303228,"accession_number":"0001104659-23-059424","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.","Cash $191.3M at March 31, 2023, down from $194.4M; cash runway into Q1 2025.","HBV002 trial met endpoints; meaningful HBsAg reductions; final data to be presented at EASL June 21-24.","APOLLO HPV trial showed favorable tolerability and T-cell responses; final 12-month data expected Q2 2024.","Appointed Nadège Pelletier as CSO; COO Chris Ellis to retire Oct 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":468000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303227,"accession_number":"0001104659-23-059138","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccitech shareholders approve all proposals at 2023 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected directors Karen T. Dawes (18.8M for) and Anne M. Phillips (19.7M for).","Re-appointed PricewaterhouseCoopers LLP as UK statutory auditors (19.7M for).","Ratified PwC as independent registered public accounting firm for FY2023 (19.7M for).","Approved advisory vote on directors' compensation report (19.7M for).","Received annual accounts for FY2022; no dividend recommended (19.7M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303226,"accession_number":"0001104659-23-052906","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vaccitech COO Chris Ellis announces retirement effective Oct 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Ellis, Chief Operating Officer (principal operating officer), informed company of retirement on April 24, 2023.","Retirement effective October 31, 2023; no replacement named.","Mr. Ellis's departure is a planned retirement, not an immediate resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322863,"accession_number":"0001104659-23-036273","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.","Revenue of $44.7M, primarily from AstraZeneca Vaxzevria milestones/royalties, up from $0.3M in 2021.","Cash of $194.4M at Dec 31, 2022, down from $214.1M; operating cash used $14.4M, capital expenditures $5.8M.","R&D expenses of $42.4M (up 108% YoY) driven by VTP-300 HBV, SNAPvax programs, and headcount growth.","Appointed Dr. Nadège Pelletier as CSO in Jan 2023; interim data readouts for VTP-300 and VTP-200 expected in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340927,"accession_number":"0001104659-22-117219","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaccitech Q3 net income $8.2M; cash $200.1M; first patient dosed in VTP-300 Phase 2b","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $8.2M ($0.22 per share) vs $15.7M in Q2 2022; revenue fell to $6.2M from $17.1M as no milestones.","Cash and equivalents $200.1M as of Sep 30, 2022, down from $214.1M at Dec 31, 2021; cash runway into Q1 2025.","Dosed first patient in Phase 2b trial of VTP-300 for HBV; Phase 1b/2a data showed HBsAg reduction in CHB patients.","Promoted Gemma Brown to CFO effective Sep 20, 2022.","Expects to open Phase 1/2 trial for prostate cancer candidate VTP-850 in Q4 2022; IND submissions for SNAPvax programs in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":38246000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358082,"accession_number":"0001104659-22-104578","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2022-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccitech grants new CFO Gemma Brown options to acquire 334,000 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Options granted on Sep 26, 2022 under the 2021 Share Award Plan.","Options vest in three equal annual installments subject to continued employment.","On death or non-misconduct termination, unvested options may vest per Board; forfeiture on misconduct."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358084,"accession_number":"0001104659-22-101580","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vaccitech promotes Gemma Brown to CFO, replacing Georgy Egorov","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gemma Brown, previously Head of Financial Reporting, appointed CFO effective Sept 15, 2022; age 32.","She receives £220k base salary and is eligible for annual bonus up to 40% of base.","Prior CFO Georgy Egorov terminated Sept 14, 2022; termination unrelated to financials or controls.","Egorov receives six months base salary severance; Brown entitled to similar payment on termination.","Brown joined Vaccitech in Sept 2021; prior experience as Senior Manager at EY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358083,"accession_number":"0001104659-22-087924","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.","Revenue $17.1M from milestone/royalty payments from AstraZeneca for Vaxzevria sales.","Cash $192.3M at June 30 vs $214.1M at Dec 31, 2021; $15.0M used in operations.","R&D expenses $9.7M (down from $10.7M); G&A excluding FX gain was $8.8M.","Clinical highlights: VTP-300 HBV data, EMA advice for MERS vaccine, HPV trial enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":32081000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376792,"accession_number":"0001104659-22-075345","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.","In monotherapy, 3 patients with baseline HBsAg <50 IU/mL had 0.7-1.4 log10 declines durable up to 8 months.","Combination group (8 patients) had mean HBsAg reduction >1 log10 at 6 months, persisting to 1.15 log10 at 8 months.","Robust T cell response with marked CD8+ predominance observed; enrollment complete at 55 patients.","Updated interim analysis for all patients at 6-month follow-up expected end of 2022; new trial dosing expected Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376791,"accession_number":"0001104659-22-071874","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccitech shareholders re-elect directors, approve auditor and compensation at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Pierre A. Morgon as director with 15,871,982 for, 1,050 against, 763 withheld.","Re-elected Joseph C.F. Scheeren as director with 15,872,082 for, 1,598 against, 115 withheld.","Appointed PricewaterhouseCoopers LLP as auditors for FY2022 with 15,873,184 for, 601 against.","Approved directors' remuneration policy with 15,871,281 for, 2,404 against, 110 withheld.","Received advisory approval of remuneration report with 15,866,826 for, 1,273 against, 5,696 withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376788,"accession_number":"0001104659-22-064100","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2022-05-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vaccitech files 8-K/A to include BDO's letter confirming auditor change agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Original 8-K on May 13, 2022 disclosed dismissal of BDO LLP and appointment of PwC as auditor.","Amendment adds BDO's letter dated May 20, 2022 (Exhibit 16.1) confirming agreement with company's statements.","No changes to original disclosures; purely procedural addition with no financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-24T23:59:59+00:00|376788"}